A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)
Joaquin Mateo,Debyani Chakravarty,R. Dienstmann,S. Jezdic,Abel Gonzalez-Perez,Nuria Lopez-Bigas,Charlotte K.Y. Ng,Philippe L. Bedard,Giampaolo Tortora,J.-Y. Douillard,E.M. Van Allen,Nikolaus Schultz,Charles Swanton,Fabrice Andre,Lajos Pusztai +14 more
Reads0
Chats0
TLDR
The first version of the ESMO Scale of Clinical Actionability for molecular Targets (ESCAT) defines clinical evidence-based criteria to prioritise genomic alterations as markers to select patients for targeted therapies.About:
This article is published in Annals of Oncology.The article was published on 2018-09-01 and is currently open access. It has received 369 citations till now. The article focuses on the topics: Precision medicine.read more
Citations
More filters
Journal ArticleDOI
Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Elizabeth C Smyth,Marcel Verheij,William H. Allum,David Cunningham,Andrés Cervantes,Dirk Arnold +5 more
Journal ArticleDOI
Pan-cancer whole-genome analyses of metastatic solid tumours
Peter Priestley,Jonathan Baber,Martijn P. Lolkema,Neeltje Steeghs,Ewart de Bruijn,Charles Shale,Korneel Duyvesteyn,Susan Haidari,Arne Van Hoeck,Wendy Onstenk,Paul Roepman,Mircea Voda,Haiko J. Bloemendal,Vivianne C. G. Tjan-Heijnen,Carla M.L. van Herpen,Mariette Labots,Petronella O. Witteveen,Egbert F. Smit,Stefan Sleijfer,Emile E. Voest,Edwin Cuppen +20 more
TL;DR: The largest, to the authors' knowledge, pan-cancer study of metastatic solid tumour genomes, including whole-genome sequencing data for 2,520 pairs of tumour and normal tissue pairs, analysed at median depths of 106× and 38×, respectively, and surveying more than 70 million somatic variants is described.
Journal ArticleDOI
Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group.
F. Mosele,Jordi Remon,Joaquin Mateo,C. B. Westphalen,Fabrice Barlesi,Martijn P. Lolkema,Nicola Normanno,Aldo Scarpa,Mark E. Robson,Funda Meric-Bernstam,Nikhil Wagle,Albrecht Stenzinger,Julia Bonastre,A. Bayle,Stefan Michiels,Ivan Bièche,Etienne Rouleau,S. Jezdic,J.-Y. Douillard,Jorge S. Reis-Filho,R. Dienstmann,Fabrice Andre +21 more
TL;DR: ESMO recommends routine use of NGS on tumour samples in advanced non-squamous NSCLC, prostate cancers, ovarian cancers and cholangiocarcinoma, and develops multigene sequencing as a tool to screen patients eligible for clinical trials and to accelerate drug development.
Journal ArticleDOI
Liquid biopsy enters the clinic - implementation issues and future challenges.
TL;DR: In this article, the authors discuss key issues and gaps in technology, clinical trial methodologies and logistics for the eventual integration of liquid biopsy into the clinical workflow, and discuss the potential applications of this technology in cancer screening and diagnosis.
Journal ArticleDOI
Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Paolo G. Casali,N. Abecassis,Sebastian Bauer,R. Biagini,Stefan S. Bielack,Sylvie Bonvalot,Ioannis Boukovinas,Judith V.M.G. Bovée,Thomas Brodowicz,Javier Martin Broto,Angela Buonadonna,E. de Álava,A. P. Dei Tos,X.G. del Muro,Palma Dileo,Mikael Eriksson,A. Fedenko,Virginia Ferraresi,Andrea Ferrari,S. Ferrari,A.M. Frezza,Silvia Gasperoni,Hans Gelderblom,Thierry Gil,Giovanni Grignani,Alessandro Gronchi,Rick L. Haas,A. Hannu,B. Hassan,Peter Hohenberger,Rolf D. Issels,Heikki Joensuu,Robin L. Jones,Ian Judson,Paul C Jutte,Suzanne E. J. Kaal,Bernd Kasper,Katerina Kopeckova,D.A. Krakorova,A. Le Cesne,Iwona Lugowska,Ofer Merimsky,Michael Montemurro,Maria Abbondanza Pantaleo,R. Piana,P. Picci,S. Piperno-Neumann,Antonio López Pousa,Peter Reichardt,M.H. Robinson,Piotr Rutkowski,Akmal Safwat,Patrick Schöffski,Stefan Sleijfer,Silvia Stacchiotti,K. Sundby Hall,M. Unk,F. van Coevorden,W.T.A. van der Graaf,Jeremy Whelan,E. Wardelmann,Olga Zaikova,Jean-Yves Blay +62 more
TL;DR: Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy; Instituto Portugues de Oncologia de Lisboa Francisco Gentil, EPE, Lisbon, Portugal; University Hospital Essen, Essen Germany; Department of Oncological Orthopedics, Musculoskeletal Tissue Bank, IFO, Regina Elena National Cancer Institute, Rome, Italy.
References
More filters
Journal ArticleDOI
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
Thomas J. Lynch,Daphne W. Bell,Raffaella Sordella,Sarada Gurubhagavatula,Ross A. Okimoto,Brian W. Brannigan,Patricia L. Harris,Sara M. Haserlat,Jeffrey G. Supko,Frank G. Haluska,David N. Louis,David C. Christiani,Jeff Settleman,Daniel A. Haber +13 more
TL;DR: A subgroup of patients with non-small-cell lung cancer have specific mutations in the EGFR gene which correlate with clinical responsiveness to the tyrosine kinase inhibitor gefitinib, and these mutations lead to increased growth factor signaling and confer susceptibility to the inhibitor.
Journal ArticleDOI
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
Dennis J. Slamon,Brian Leyland-Jones,Steven Shak,Hank Fuchs,Virginia E. Paton,Alex Bajamonde,Thomas Fleming,Wolfgang Eiermann,Janet M. Wolter,Mark D. Pegram,José Baselga,Larry Norton +11 more
TL;DR: The addition of trastuzumab to chemotherapy was associated with a longer time to disease progression, a higher rate of objective response, a longer duration of response, and a lower rate of death at 1 year.
Journal ArticleDOI
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Dung T. Le,Jennifer N. Uram,Hao Wang,Bjarne Bartlett,Holly Kemberling,Aleksandra Eyring,Andrew D. Skora,Brandon Luber,Nilofer S. Azad,Daniel A. Laheru,Barbara A. Biedrzycki,Ross C. Donehower,Atif Zaheer,George A. Fisher,Todd S. Crocenzi,James J. Lee,Steven M. Duffy,Richard M. Goldberg,Richard M. Goldberg,Albert de la Chapelle,Albert de la Chapelle,Minori Koshiji,Feriyl Bhaijee,Thomas Huebner,Ralph H. Hruban,Laura D. Wood,Nathan Cuka,Drew M. Pardoll,Nickolas Papadopoulos,Kenneth W. Kinzler,Shibin Zhou,Toby C. Cornish,Janis M. Taube,Robert A. Anders,James R. Eshleman,Bert Vogelstein,Luis A. Diaz +36 more
TL;DR: This study showed that mismatch-repair status predicted clinical benefit of immune checkpoint blockade with pembrolizumab, and high somatic mutation loads were associated with prolonged progression-free survival.
Journal ArticleDOI
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman,Axel Hauschild,Caroline Robert,John B. A. G. Haanen,Paolo A. Ascierto,James Larkin,Reinhard Dummer,Claus Garbe,Alessandro Testori,Michele Maio,David W. Hogg,Paul Lorigan,Céleste Lebbé,Thomas Jouary,Dirk Schadendorf,Antoni Ribas,Jeffrey A. Sosman,John M. Kirkwood,Brigitte Dréno,K. B. Nolop,Jiang Li,B. Nelson,Jeannie Hou,Richard J. Lee,Keith T. Flaherty,Grant A. McArthur +25 more
TL;DR: Vemurafenib produced improved rates of overall and progression-free survival in patients with previously untreated melanoma with the BRAF V600E mutation in a phase 3 randomized clinical trial.
Journal ArticleDOI
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Hannah Farmer,Nuala McCabe,Christopher J. Lord,Andrew Tutt,Andrew Tutt,Damian A. Johnson,Tobias B. Richardson,Manuela Santarosa,Krystyna J. Dillon,Ian Hickson,Charlotte Knights,Niall M. B. Martin,Stephen P. Jackson,Graeme C. M. Smith,Alan Ashworth +14 more
TL;DR: BRCA1 or BRCA2 dysfunction unexpectedly and profoundly sensitizes cells to the inhibition of PARP enzymatic activity, resulting in chromosomal instability, cell cycle arrest and subsequent apoptosis, illustrating how different pathways cooperate to repair damage.
Related Papers (5)
OncoKB: A Precision Oncology Knowledge Base.
Debyani Chakravarty,Jianjiong Gao,Sarah Fierberg Phillips,Ritika Kundra,Hongxin Zhang,Jiaojiao Wang,Julia E. Rudolph,Rona Yaeger,Tara Soumerai,Moriah H. Nissan,Matthew T. Chang,Sarat Chandarlapaty,Tiffany A. Traina,Paul K. Paik,Alan L. Ho,Feras M. Hantash,Andrew Grupe,Shrujal S. Baxi,Margaret K. Callahan,Alexandra Snyder,Ping Chi,Daniel C. Danila,Mrinal Gounder,James J. Harding,Matthew D. Hellmann,Gopa Iyer,Yelena Y. Janjigian,Thomas Kaley,Douglas A. Levine,Maeve A. Lowery,Antonio M. P. Omuro,Michael A. Postow,Dana Rathkopf,Alexander N. Shoushtari,Neerav Shukla,Martin H. Voss,Ederlinda Paraiso,Ahmet Zehir,Michael F. Berger,Barry S. Taylor,Leonard B. Saltz,Gregory J. Riely,Marc Ladanyi,David M. Hyman,José Baselga,Paul Sabbatini,David B. Solit,Nikolaus Schultz +47 more
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
Alexander Drilon,Theodore W. Laetsch,Shivaani Kummar,Steven G. DuBois,Ulrik Lassen,George D. Demetri,Michael J. Nathenson,Robert C. Doebele,Anna F. Farago,Alberto S. Pappo,Brian Turpin,Afshin Dowlati,Marcia S. Brose,Leo Mascarenhas,Noah Federman,Jordan Berlin,Wafik S. El-Deiry,Christina S. Baik,John F. Deeken,Valentina Boni,Ramamoorthy Nagasubramanian,Matthew H. Taylor,Erin R. Rudzinski,Funda Meric-Bernstam,Davendra Sohal,Patrick C. Ma,Luis E. Raez,Jaclyn F. Hechtman,Ryma Benayed,Marc Ladanyi,Brian B. Tuch,Kevin Ebata,Scott Cruickshank,Nora Ku,Michael C. Cox,Douglas S. Hawkins,David S. Hong,David S. Hong,David M. Hyman +38 more
Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial
Christophe Le Tourneau,Christophe Le Tourneau,Jean Pierre Delord,Anthony Gonçalves,Céline Gavoille,Coraline Dubot,Nicolas Isambert,Mario Campone,Ol vier Trédan,Marie Ange Massiani,Cecile Mauborgne,Sebastien Armanet,Nicolas Servant,Ivan Bièche,Virginie Bernard,David Gentien,Pascal Jézéquel,Valéry Attignon,Sandrine Boyault,Anne Vincent-Salomon,Vincent Servois,Marie Paule Sablin,Maud Kamal,Xavier Paoletti,Xavier Paoletti +24 more
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
Ahmet Zehir,Ryma Benayed,Ronak Shah,Aijazuddin Syed,Sumit Middha,Hyunjae R. Kim,Preethi Srinivasan,Jianjiong Gao,Debyani Chakravarty,Sean M. Devlin,Matthew D. Hellmann,David Barron,Alison M. Schram,Meera Hameed,Snjezana Dogan,Dara S. Ross,Jaclyn F. Hechtman,Deborah DeLair,Jinjuan Yao,Diana Mandelker,Donavan T. Cheng,Raghu Chandramohan,Abhinita Mohanty,Ryan Ptashkin,Gowtham Jayakumaran,Meera Prasad,Mustafa H Syed,Anoop Balakrishnan Rema,Zhen Y Liu,Khedoudja Nafa,Laetitia Borsu,Justyna Sadowska,Jacklyn Casanova,Ruben Bacares,Iwona Kiecka,Anna Razumova,Julie B Son,Lisa Stewart,Tessara Baldi,Kerry Mullaney,Hikmat Al-Ahmadie,Efsevia Vakiani,Adam Abeshouse,Alexander V Penson,Philip Jonsson,Niedzica Camacho,Matthew T. Chang,Helen Won,Benjamin Gross,Ritika Kundra,Zachary J. Heins,Hsiao-Wei Chen,Sarah Phillips,Hongxin Zhang,Jiaojiao Wang,Angelica Ochoa,Jonathan Wills,Michael H. Eubank,Stacy B. Thomas,Stuart Gardos,Dalicia N. Reales,Jesse Galle,Robert Durany,Roy Cambria,Wassim Abida,Andrea Cercek,Darren R. Feldman,Mrinal M. Gounder,A. Ari Hakimi,James J. Harding,Gopa Iyer,Yelena Y. Janjigian,Emmet Jordan,Ciara Marie Kelly,Maeve A. Lowery,Luc G. T. Morris,Antonio Omuro,Nitya Raj,Pedram Razavi,Alexander N. Shoushtari,Neerav Shukla,Tara Soumerai,Anna M. Varghese,Rona Yaeger,Jonathan A. Coleman,Bernard H. Bochner,Gregory J. Riely,Leonard B. Saltz,Howard I. Scher,Paul Sabbatini,Mark E. Robson,David S. Klimstra,Barry S. Taylor,José Baselga,Nikolaus Schultz,David M. Hyman,Maria E. Arcila,David B. Solit,Marc Ladanyi,Michael F. Berger +99 more